✦ LIBER ✦

P-633 Non-small cell lung cancer (NSCLC) patients with undetectable epidermal growth factor receptor (EGFR) expression respond poorly to ZD1839 (Iressa)

✍ Scribed by Polowy, Clayton R.; Coon, John S.; Leslie, William T.; DiNunno, Lucio; Lukic, Ivanka; Kanevsky, Gina; Gale, Meryl; Morrison, Larry E.; Seelig, Steven A.; Bonomi, Philip

Book ID: 118572328
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 184 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92600-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor targete

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

✍ Cappuzzo, Federico; Ardizzoni, Andrea; Soto-Parra, Hector; Gridelli, Cesare; Mai 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer

✍ Sae-Won Han; Pil Gyu Hwang; Doo Hyun Chung; Dong-Wan Kim; Seock-Ah Im; Young Tae 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 351 KB 👁 1 views

## Abstract Gefitinib has shown meaningful antitumor activity with tolerable toxicity in chemotherapy‐refractory NSCLC in previous studies. Moreover, EGFR expression failed to show a correlation with response. In an attempt to identify predictive markers of response, we have investigated the tumora

Pilot trial of ZD1839 (IressaTM), an ora

Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

✍ Laurie, S.A; Miller, V.A; Johnson, D; Ng, K.K; Heelan, R.T; Pizzo, B.A; Perez, W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

1148 POSTER DAB2 Interactive Protein (DA

1148 POSTER DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Mutations

✍ J.W. Wei; J.L.R. Jose Luis Ramirez; M.T Miquel Taron; J.J.S. Jose Javier Sanchez 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB